Esperion Therapeutics (ESPR) EPS Estimated At $-1.67, Oak Ridge Investments Has Trimmed Ligand Pharm (LGND) Holding By $14.44 Million

July 17, 2017 - By Linda Rogers

Oak Ridge Investments Llc decreased Ligand Pharm Inc (LGND) stake by 17.65% reported in 2016Q4 SEC filing. Oak Ridge Investments Llc sold 142,929 shares as Ligand Pharm Inc (LGND)’s stock rose 7.66%. The Oak Ridge Investments Llc holds 667,093 shares with $67.78M value, down from 810,022 last quarter. Ligand Pharm Inc now has $2.45B valuation. The stock declined 1.15% or $1.37 reaching $117.28 per share. About 80,675 shares traded. Ligand Pharmaceuticals Inc. (NASDAQ:LGND) has declined 2.87% since July 17, 2016 and is downtrending. It has underperformed by 19.57% the S&P500.

Analysts expect Esperion Therapeutics Inc (NASDAQ:ESPR) to report $-1.67 EPS on August, 3.They anticipate $1.05 EPS change or 169.35% from last quarter’s $-0.62 EPS. After having $-1.80 EPS previously, Esperion Therapeutics Inc’s analysts see -7.22% EPS growth. About 262,837 shares traded. Esperion Therapeutics Inc (NASDAQ:ESPR) has risen 133.75% since July 17, 2016 and is uptrending. It has outperformed by 117.05% the S&P500.

Among 5 analysts covering Ligand Pharmaceuticals (NASDAQ:LGND), 4 have Buy rating, 1 Sell and 0 Hold. Therefore 80% are positive. Ligand Pharmaceuticals had 12 analyst reports since September 3, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Monday, September 21 by Roth Capital. The stock of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) earned “Buy” rating by TH Capital on Thursday, November 19. TH Capital maintained the shares of LGND in report on Wednesday, September 30 with “Buy” rating. The company was maintained on Wednesday, September 30 by Roth Capital. The firm earned “Sell” rating on Friday, August 5 by Deutsche Bank. The stock of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) has “Buy” rating given on Thursday, November 19 by Roth Capital. The stock has “Buy” rating by Roth Capital on Thursday, September 3. On Friday, March 11 the stock rating was maintained by Roth Capital with “Buy”. The firm has “Overweight” rating given on Wednesday, April 13 by Stephens. The stock of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) has “Buy” rating given on Wednesday, October 5 by H.C. Wainwright.

Oak Ridge Investments Llc increased A O Smith (NYSE:AOS) stake by 484,567 shares to 1.34M valued at $63.65 million in 2016Q4. It also upped Dicks Sporting Goods Com (NYSE:DKS) stake by 107,380 shares and now owns 145,329 shares. I Shares Russell 2000 Growth (IWO) was raised too.

Analysts await Ligand Pharmaceuticals Inc. (NASDAQ:LGND) to report earnings on August, 3. They expect $0.25 EPS, up 47.06% or $0.08 from last year’s $0.17 per share. LGND’s profit will be $5.22 million for 117.28 P/E if the $0.25 EPS becomes a reality. After $0.39 actual EPS reported by Ligand Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts -35.90% negative EPS growth.

Since February 27, 2017, it had 0 insider purchases, and 7 selling transactions for $11.11 million activity. 6,879 shares valued at $711,214 were sold by FOEHR MATTHEW W on Thursday, March 2. Shares for $428,240 were sold by HIGGINS JOHN L. 37,247 shares valued at $4.13 million were sold by Aryeh Jason on Thursday, May 11.

Investors sentiment increased to 1.2 in Q4 2016. Its up 0.12, from 1.08 in 2016Q3. It increased, as 23 investors sold LGND shares while 85 reduced holdings. 39 funds opened positions while 91 raised stakes. 22.77 million shares or 1.00% less from 23.00 million shares in 2016Q3 were reported. Columbia Wanger Asset Mgmt Limited Liability reported 0.13% in Ligand Pharmaceuticals Inc. (NASDAQ:LGND). Moreover, Sector Pension Board has 0.01% invested in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) for 13,447 shares. Gemmer Asset Mgmt Limited Liability holds 0% in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) or 51 shares. Fmr Ltd Liability accumulated 486,063 shares or 0.01% of the stock. Prudential Fincl accumulated 66,748 shares. Clearbridge Limited Liability accumulated 81,055 shares. Old Mutual Glob Investors (Uk) Ltd reported 5,468 shares. Pictet Asset Mngmt Ltd invested 0.01% in Ligand Pharmaceuticals Inc. (NASDAQ:LGND). Clarivest Asset Management Ltd Liability Corporation invested 0.05% of its portfolio in Ligand Pharmaceuticals Inc. (NASDAQ:LGND). Clearbridge Invests Lc invested in 111 shares. State Board Of Administration Of Florida Retirement Systems holds 0% in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) or 11,790 shares. Nordea Investment Management holds 0% or 11,328 shares in its portfolio. Moreover, Mason Street Ltd Co has 0.01% invested in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) for 4,156 shares. Colorado-based Janus Capital Management Ltd Liability Corp has invested 0.02% in Ligand Pharmaceuticals Inc. (NASDAQ:LGND). Thrivent For Lutherans reported 0% in Ligand Pharmaceuticals Inc. (NASDAQ:LGND).

Esperion Therapeutics, Inc. is a lipid management company. The company has market cap of $1.13 billion. The Firm is a late-stage pharmaceutical firm focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol . It currently has negative earnings. With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Investors sentiment decreased to 0.88 in 2016 Q4. Its down 0.28, from 1.16 in 2016Q3. It dived, as 15 investors sold Esperion Therapeutics Inc shares while 27 reduced holdings. 12 funds opened positions while 25 raised stakes. 14.57 million shares or 2.54% more from 14.20 million shares in 2016Q3 were reported. Int Group Inc holds 0% or 8,230 shares. Blackrock Mgmt Llc accumulated 0% or 59,959 shares. Financial Bank Of America De invested in 110,523 shares or 0% of the stock. Ny State Common Retirement Fund holds 0% of its portfolio in Esperion Therapeutics Inc (NASDAQ:ESPR) for 13,100 shares. Kennedy Mngmt Inc holds 239,054 shares. State Street holds 0% or 238,482 shares in its portfolio. Blackrock Institutional Trust Co Na reported 398,499 shares. Tiaa Cref Inv Ltd Liability Corp holds 0% of its portfolio in Esperion Therapeutics Inc (NASDAQ:ESPR) for 38,910 shares. 50,711 are owned by Martingale Asset Mgmt Ltd Partnership. Alliancebernstein Ltd Partnership reported 0% of its portfolio in Esperion Therapeutics Inc (NASDAQ:ESPR). Blackrock Grp has 5,811 shares. Jpmorgan Chase & Company holds 0% or 196,500 shares. Keybank Association Oh holds 0% of its portfolio in Esperion Therapeutics Inc (NASDAQ:ESPR) for 12,691 shares. Vanguard Grp has 600,832 shares. Tekla Capital Mngmt Limited Liability Corp accumulated 102,800 shares.

Among 15 analysts covering Esperion Therapeutics (NASDAQ:ESPR), 8 have Buy rating, 0 Sell and 7 Hold. Therefore 53% are positive. Esperion Therapeutics had 39 analyst reports since July 28, 2015 according to SRatingsIntel. The firm has “Buy” rating by Needham given on Thursday, June 30. The firm earned “Sector Perform” rating on Wednesday, June 29 by RBC Capital Markets. Citigroup maintained it with “Buy” rating and $22 target in Wednesday, June 29 report. RBC Capital Markets maintained it with “Outperform” rating and $40 target in Tuesday, December 15 report. Credit Suisse downgraded it to “Underperform” rating and $10 target in Wednesday, June 29 report. The rating was initiated by Lake Street with “Buy” on Monday, October 26. The company was maintained on Thursday, February 25 by Stifel Nicolaus. Barclays Capital maintained the shares of ESPR in report on Wednesday, February 24 with “Overweight” rating. The stock of Esperion Therapeutics Inc (NASDAQ:ESPR) earned “Sell” rating by Chardan Capital Markets on Monday, August 31. The rating was maintained by Chardan Capital Markets on Friday, February 26 with “Neutral”.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>